These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 34724213)

  • 21. Effect of phthalocyanine oral and nasal antiseptic solutions on the infectivity of SARS-CoV-2 in patients with COVID-19: a randomized controlled trial.
    Colado Simão AN; Perugini Stadtlober N; Stinghen Garcia Lonni AA; Venâncio LM; Lerner Trigo G; de Souza Cassela PLC; Mastellini Sanches Silva T; De Fátima Oliveira Hirth Ruiz M; Batisti Lozovoy MA; Tano ZN; da Fonseca Orcina B; Vieira Vilhena F; da Silva Santos PS
    Ger Med Sci; 2023; 21():Doc07. PubMed ID: 37426884
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in reverse transcription polymerase chain reaction cycle threshold values of SARS-CoV-2 with topical povidone iodine use: A single-arm open-label interventional study.
    Shankar S; Jamir L; Kakkar R; Babji K; Mangayarkarasi V; Tripathi M; Tak H
    J Family Med Prim Care; 2022 Feb; 11(2):480-486. PubMed ID: 35360801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nasopharyngeal Wash with Normal Saline Decreases SARS-CoV-2 Viral Load: A Randomized Pilot Controlled Trial.
    Pantazopoulos I; Chalkias A; Mavrovounis G; Dimeas I; Sinis S; Miziou A; Rouka E; Poulas K; Gourgoulianis K
    Can Respir J; 2022; 2022():8794127. PubMed ID: 36247079
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of Povidone-Iodine Nasal and Oral Antiseptic Preparations Against Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2).
    Pelletier JS; Tessema B; Frank S; Westover JB; Brown SM; Capriotti JA
    Ear Nose Throat J; 2021 Apr; 100(2_suppl):192S-196S. PubMed ID: 32951446
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Repurposing 0.5% povidone iodine solution in otorhinolaryngology practice in Covid 19 pandemic.
    Khan MM; Parab SR; Paranjape M
    Am J Otolaryngol; 2020; 41(5):102618. PubMed ID: 32574894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A quadruple blind, randomised controlled trial of gargling agents in reducing intraoral viral load among hospitalised COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial.
    Khan FR; Kazmi SMR; Iqbal NT; Iqbal J; Ali ST; Abbas SA
    Trials; 2020 Sep; 21(1):785. PubMed ID: 32928313
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of mouthwash on reducing salivary SARS-CoV-2 viral load and clinical symptoms: a systematic review and meta-analysis.
    Zhang M; Meng N; Duo H; Yang Y; Dong Q; Gu J
    BMC Infect Dis; 2023 Oct; 23(1):678. PubMed ID: 37821800
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In Vitro Efficacy of a Povidone-Iodine Nasal Antiseptic for Rapid Inactivation of SARS-CoV-2.
    Frank S; Brown SM; Capriotti JA; Westover JB; Pelletier JS; Tessema B
    JAMA Otolaryngol Head Neck Surg; 2020 Nov; 146(11):1054-1058. PubMed ID: 32940656
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo evaluation of the virucidal efficacy of chlorhexidine and povidone-iodine mouthwashes against salivary SARS-CoV-2. A randomized-controlled clinical trial.
    Elzein R; Abdel-Sater F; Fakhreddine S; Hanna PA; Feghali R; Hamad H; Ayoub F
    J Evid Based Dent Pract; 2021 Sep; 21(3):101584. PubMed ID: 34479668
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The short-term effect of different chlorhexidine forms versus povidone iodine mouth rinse in minimizing the oral SARS-CoV-2 viral load: An open label randomized controlled clinical trial study.
    Natto ZS; Bakhrebah MA; Afeef M; Al-Harbi S; Nassar MS; Alhetheel AF; Ashi H
    Medicine (Baltimore); 2022 Jul; 101(30):e28925. PubMed ID: 35905275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Virucidal effect of povidone-iodine against SARS-CoV-2
    Wang Y; Wu Y; Wang Q; Zhu J; Shi W; Han Z; Zhang Y; Chen K
    J Int Med Res; 2021 Dec; 49(12):3000605211063695. PubMed ID: 34914884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.
    Lyngbakken MN; Berdal JE; Eskesen A; Kvale D; Olsen IC; Rangberg A; Jonassen CM; Omland T; Røsjø H; Dalgard O
    Trials; 2020 Jun; 21(1):485. PubMed ID: 32503662
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Povidone Iodine (PVP-I) Oro-Nasal Spray: An Effective Shield for COVID-19 Protection for Health Care Worker (HCW), for all.
    Arefin MK
    Indian J Otolaryngol Head Neck Surg; 2022 Oct; 74(Suppl 2):2906-2911. PubMed ID: 33846691
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Virucidal activity of nasal sprays against severe acute respiratory syndrome coronavirus-2.
    Meister TL; Todt D; Brüggemann Y; Steinmann J; Banava S; Brill FHH; Steinmann J; Pfaender S; Steinmann E
    J Hosp Infect; 2022 Feb; 120():9-13. PubMed ID: 34752803
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Review of the use of nasal and oral antiseptics during a global pandemic.
    Stathis C; Victoria N; Loomis K; Nguyen SA; Eggers M; Septimus E; Safdar N
    Future Microbiol; 2021 Jan; 16(2):119-130. PubMed ID: 33464122
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Povidone-Iodine as a Pre-Procedural Mouthwash to Reduce the Salivary Viral Load of SARS-CoV-2: A Systematic Review of Randomized Controlled Trials.
    Garcia-Sanchez A; Peña-Cardelles JF; Ordonez-Fernandez E; Montero-Alonso M; Kewalramani N; Salgado-Peralvo AO; Végh D; Gargano A; Parra G; Guerra-Guajardo LI; Kozuma W
    Int J Environ Res Public Health; 2022 Mar; 19(5):. PubMed ID: 35270569
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Povidone-Iodine Demonstrates Rapid In Vitro Virucidal Activity Against SARS-CoV-2, The Virus Causing COVID-19 Disease.
    Anderson DE; Sivalingam V; Kang AEZ; Ananthanarayanan A; Arumugam H; Jenkins TM; Hadjiat Y; Eggers M
    Infect Dis Ther; 2020 Sep; 9(3):669-675. PubMed ID: 32643111
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapid initiation of nasal saline irrigation to reduce severity in high-risk COVID+ outpatients.
    Baxter AL; Schwartz KR; Johnson RW; Kuchinski AM; Swartout KM; Srinivasa Rao ASR; Gibson RW; Cherian E; Giller T; Boomer H; Lyon M; Schwartz R
    Ear Nose Throat J; 2024 Jun; 103(1_suppl):30S-39S. PubMed ID: 36007135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early intervention with azelastine nasal spray may reduce viral load in SARS-CoV-2 infected patients.
    Klussmann JP; Grosheva M; Meiser P; Lehmann C; Nagy E; Szijártó V; Nagy G; Konrat R; Flegel M; Holzer F; Groß D; Steinmetz C; Scherer B; Gruell H; Schlotz M; Klein F; de Aragão PA; Morr H; Al Saleh H; Bilstein A; Russo B; Müller-Scholtz S; Acikel C; Sahin H; Werkhäuser N; Allekotte S; Mösges R
    Sci Rep; 2023 Apr; 13(1):6839. PubMed ID: 37100830
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nasal spray of an IgM-like ACE2 fusion protein HH-120 accelerates SARS-CoV-2 clearance: A single-center propensity score-matched cohort study.
    Song R; Chen X; Li B; Zhang H; Guo X; Liu Z; Zou L; Liang X; Lei C; Mao F; Sui J; Li W; Jin R
    J Med Virol; 2023 May; 95(5):e28805. PubMed ID: 37227062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.